Key result
Long-term survivors of sarcoma (>5 years) remain at significant risk for late disease recurrence, shortened lifespan, and increased cardiovascular morbidity, requiring specialty follow-up.
Answers are grounded in this paper and cite their sources.
Highlights the critical role for long-term specialty follow-up in sarcoma survivors due to risks of late recurrence and cardiovascular morbidity.
Because sarcomas are rare (1% of all adult solid malignancies) and encompass a heterogeneous group of tumors (> 50 subtypes), information regarding late recurrences for patients with resected soft tissue sarcomas, although recognized to occur, is not well defined. Details concerning late recurrences, such as the frequencies, risk factors, and relative rates between tumor subtypes, depend on the existence of a large, well‐annotated, multiinstitutional, accurate database that spans several decades of clinical experience. The French Sarcoma Group has assembled such a database, and they report with accuracy and detail what happens to patients with sarcoma after they survive for > 5 years. Recognition that a significant percentage of long‐term survivors of sarcoma are still at risk of developing late disease recurrence can be paired with the growing awareness that they are also at risk of a shortened lifespan and increased cardiovascular and psychological morbidity to highlight a critical role for long‐term specialty follow‐up.
No takes yet. Share an insight, caveat, or question.
Edwin Choy (2014) conducted an editorial in Resected soft tissue sarcomas. Survival > 5 years was evaluated on Late disease recurrence, shortened lifespan, and increased cardiovascular and psychological morbidity. Long-term survivors of sarcoma (>5 years) remain at significant risk for late disease recurrence, shortened lifespan, and increased cardiovascular morbidity, requiring specialty follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: